Chemotherapy of MMR-deficient colorectal cancer

Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer

(2011) Gordon Hutchins et al.   JOURNAL OF CLINICAL ONCOLOGY

Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer

(2010) Daniel J. Sargent et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Relevance of Microsatellite Instability in Colorectal Cancer

(2010) Albert de la Chapelle et al.   JOURNAL OF CLINICAL ONCOLOGY

DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer

(2010) Frank A. Sinicrope   Nature Reviews Clinical Oncology

Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin

(2009) A. Zaanan et al.   ANNALS OF ONCOLOGY

Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy

(2009) Seung Tae Kim et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Angiotensinogen Delays Angiogenesis and Tumor Growth of Hepatocarcinoma in Transgenic Mice

(2009) F. Vincent et al.   CANCER RESEARCH

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair geneMSH2

(2009) Sarah A. Martin et al.   EMBO Molecular Medicine

Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial

(2009) Thierry André et al.   JOURNAL OF CLINICAL ONCOLOGY

The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer

(2009) Seung Tae Kim et al.   MEDICAL ONCOLOGY

Molecular Characterization of MSI-H Colorectal Cancer by MLHI Promoter Methylation, Immunohistochemistry, and Mismatch Repair Germline Mutation Screening

(2008) J. N. Poynter et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION